Últimas noticias sobre Novavax (NASDAQ:NVAX) Bolsa

Novavax

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.

Novavax Inc

NOVAVAX ORD

President-elect Donald Trump picked Robert F. Kennedy Jr., known for his vaccine skepticism, as his nominee Thursday to lead the <a href="https://www.benzinga.com/general/biotech/24/10/41127143/us-hhs-reveal-cost-savings-for-54-prescription-drugs-including-novartis-cancer-drug-ozempic-could">Department of Health and Human Services. </a>
This move, which comes after Kennedy ended his presidential campaign and endorsed Trump, positions the environmental activist to potentially reshape national health policies. The selection has stirred mixed reactions, particularly from public health experts, <a href="https://www.politico.com/news/2024/11/14/robert-f-kennedy-jr-trump-hhs-secretary-pick-00188617">Politico</a> reports.
&#8220;For too long, Americans have been crushed by the industrial food complex and drug companies who have engaged in deception, misinformation, and disinformation when it comes to Public Health,&#8221; Trump said in a tweet announcing the decision. 
As Benzinga reported earlier this month, Kennedy has a history of spreading falsehoods about vaccines, including that they cause autism, a theory disproven by scientific studies. His selection as the nominee for HHS secretary comes against a backdrop of falling vaccination rates, which coincide with, in one example, 13 measles outbreaks in the U.S. so far this year. 
What Happened: Trump's decision is part of a broader promise to "let Kennedy go wild" with health and food policies, aiming to overhaul the HHS. Kennedy has expressed sharp criticisms of several health agencies.
Kennedy had hinted at the potential role of "health czar" in Trump&#8217;s administration. If he is confirmed, Kennedy's appointment could influence vaccine policy and the <a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">direction of the CDC, FDA, and NIH.</a>
Also Read: <a href="https://www.benzinga.com/trading-ideas/24/11/41977313/will-trumps-election-win-push-sp-500-even-higher-in-final-weeks-of-2024-over-75-say">Will Trump&#8217;s Election Win Push S&amp;P 500 Even Higher In Final Weeks Of 2024? Over 75% Say&#8230;</a>
Kennedy's prospective role has already affected vaccine manufacturer stocks. Major vaccine-related companies saw declines in stock prices on Thursday due to the uncertainty surrounding Kennedy&#8217;s influence on health policy.
Key companies impacted include:
<ul>
<li>Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) down 5.62% to $39.77.</li>
<li>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) down 2.62% to $26.02.</li>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) down 0.89% to $151.87.</li>
<li>AstraZeneca plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) down 0.38% to $65.04.</li>
<li>Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) down 7.02% to $7.22.</li>
</ul>
Why It Matters: Kennedy's views on vaccines and health oversight agencies stand in stark contrast to established medical consensus. His appointment could alter public health directives, with some analysts predicting potential shifts in FDA regulatory independence and vaccine guidelines. 
The impact may extend beyond policy, shaping public trust in health systems amid ongoing debates over vaccine safety.
Kennedy, while indicating he has no plans to "take away anybody's vaccines," continues to be a polarizing figure. Vaccine-related stocks may experience ongoing volatility as the Trump administration finalizes its health policy agenda.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41988194/trump-plans-to-erase-ev-tax-credit-analyst-says-its-net-bullish-calls-sell-off-wrong-knee-jerk-reaction">Trump Plans To Erase EV Tax Credit: Tesla Analyst Says It&#8217;s &#8216;Net Bullish,&#8217; Calls Sell-Off &#8216;Wrong Knee-Jerk Reaction&#8217;</a></li>
</ul>
Photo: Shutterstock.

Equities

Government

News

Regulations

Health Care

Politics

Markets

Movers

MRNA

NVAX

Trump Taps RFK Jr. For Health Secretary Role, Sends 5 Vaccine Stocks Lower

<a href="https://x.com/DonaldJTrumpJr/status/1857168002837352564" title="https://x.com/DonaldJTrumpJr/status/1857168002837352564">https://x.com/DonaldJTrumpJr/status/1857168002837352564</a>

Biotech

General

BNTX

Donald Trump Jr. Posts On X "Robert F Kennedy Jr will be The Secretary of Health and Human Services! Promises Made Promises Kept"

WIIM

Shares of vaccine stocks are trading lower following a report suggesting president-elect Trump is expected to nominate Robert F. Kennedy Jr. to lead the HHS.

<a href="https://www.politico.com/news/2024/11/14/robert-f-kennedy-jr-trump-hhs-secretary-pick-00188617">https://www.politico.com/news/2024/11/14/robert-f-kennedy-jr-trump-hhs-secretary-pick-00188617</a>
&nbsp;
President-elect Donald Trump is expected to nominate former presidential candidate and anti-vaccine activist Robert F. Kennedy Jr. to lead the Department of Health and Human Services, according to a person with direct knowledge of the selection.
The expected pick, which will roil many public health experts, comes after Trump promised to let Kennedy <a href="https://www.politico.com/video/2024/10/28/trump-says-he-would-let-rfk-jr-go-wild-on-medicines-1466853">"go wild" with health</a> and food policy in his administration after Kennedy dropped his own presidential bid to endorse the now-president-elect. It's also a sign of the opening Trump sees after he scored a decisive electoral victory and Republicans won a comfortable majority in the Senate.
Trump could still select someone else for the post. The Trump transition couldn't immediately be reached for comment.
"He's going to help make America healthy again. … He wants to do some things, and we're going to let him get to it," Trump said in his victory speech. "Go have a good time, Bobby."

Trading Ideas

'Trump Expected To Select Robert F. Kennedy Jr. To Lead HHS; The Choice Will Roil Many Public Health Experts After His Years Of Touting Debunked Claims That Vaccines Cause Autism' - Politico

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) with a Buy and maintains $19 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Novavax, Maintains $19 Price Target

On Tuesday,&nbsp;Novavax Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>)&nbsp;reported third-quarter 2024 sales of $84.5 million, compared to&nbsp;$186.99 million&nbsp;a year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $65.78 million</a>.
Product sales of $38 million for the third quarter of 2024 were primarily related to U.S. market commercial sales. Licensing, royalties, and other revenue of $46 million in the third quarter of 2024 related to a combination of activities under the Sanofi Agreement and adjuvant sales.
In September, the FDA granted Emergency Use Authorization to&nbsp;Novavax&#8217;s COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705), for active immunization to prevent COVID-19 in&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40688052/fda-approves-novavaxs-updated-covid-vaccine-targeting-currently-circulating-variants" rel="noreferrer noopener">individuals aged 12 and older</a>.
The COVID-19 vaccine maker reported an EPS loss of 76 cents, up from a $1.26 loss a year ago, beating the consensus of 83 cents loss.
The net loss for the third quarter of 2024 was $121 million, compared to $131 million in the same period in 2023.
&#8220;Novavax continues to focus on our corporate growth strategy of driving value from additional business development activities and organic R&amp;D using our proven technology platform,&#8221; said John C. Jacobs, President and CEO of Novavax.
&#8220;In addition to progress on our other value drivers, this past quarter, we made significant progress defining our R&amp;D strategy as we look to expand beyond COVID-19 and influenza.&#8221;
Recently,&nbsp;the FDA removed the clinical hold on&nbsp;Novavax&#8217;s Investigational New Drug application for its COVID-19-influenza combination and stand-alone&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41878334/fda-gives-green-signal-to-novavaxs-covid-19-influenza-combo-vaccine-late-stage-trial" rel="noreferrer noopener">influenza vaccine candidates</a>.
Last week, Novavax and the U.K. Health Security Agency, representing the U.K. Secretary of State for Health and Social Care, signed a Termination and Settlement Agreement and an amendment to resolve disputes over their updated COVID-19 vaccine supply contract from <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41782824/why-is-covid-19-vaccine-maker-novavax-stock-trading-lower-on-wednesday" rel="noreferrer noopener">July 1, 2022</a>.
Guidance: Novavax expects 2024 revenues of $650 million—$700 million, compared to prior guidance of $700 million—$800 million and a consensus of $761.5 million.
The company says full-year 2024 product sales guidance of $175 million-$225 million (vs. prior guidance of $275 million-$375 million) reflects approximately $100 million in APA dose deliveries in 1H 2024 and $75 million-$125 million in commercial market sales in 2H 2024.
Price Action: NVAX stock is down 11.20% at $8.01 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/24/11/41899460/boeing-lands-737-8-deal-with-avia-solutions-40-planes-now-40-more-to-follow" target="_blank" rel="noreferrer noopener">Boeing Lands 737-8 Deal With Avia Solutions: 40 Planes Now, 40 More To Follow</a></li>
</ul>
Photo by Vladimka production via Shutterstock

Earnings

Guidance

Novavax Lowers 2024 Forecast Despite Q3 Revenue Beat, Stock Falls

Novavax shares are trading lower after the company lowered its 2024 revenue guidance to $650M-$700M, below prior guidance and analyst expectations.

Financial Framework
Novavax is updating its Full Year 2024 Financial Guidance and expects to achieve the following objectives.
Full Year 2024 Guidance
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">
&nbsp;
$ in millions
</td>
<td colspan="1" rowspan="1">
Prior
(as of Aug. 8, 2024)
</td>
<td colspan="1" rowspan="1">
Updated
(as of Nov. 12, 2024)
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Revenue</td>
<td colspan="1" rowspan="1">$700 - $800</td>
<td colspan="1" rowspan="1">$650 - $700</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Product Sales&nbsp;</td>
<td colspan="1" rowspan="1">$275 - $375</td>
<td colspan="1" rowspan="1">$175 - $225</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Licensing, Royalties and Other Revenue&nbsp;</td>
<td colspan="1" rowspan="1">$425</td>
<td colspan="1" rowspan="1">$475</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Combined R&amp;D and SG&amp;A</td>
<td colspan="1" rowspan="1">$700 - $750</td>
<td colspan="1" rowspan="1">$700 - $750</td>
</tr>
</tbody>
</table>
</figure>

Novavax Expects 2024 Total Revenues Of $650M-$700M Versus Prior Guidance Of $700M-$800M And Consensus Of $761.458M

Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(0.83) by 8.43 percent. The company reported quarterly sales of $84.51 million which beat the analyst consensus estimate of $65.78 million by 28.49 percent. This is a 54.80 percent decrease over sales of $186.99 million the same period last year.

Novavax Q3 2024 GAAP EPS $(0.76) Beats $(0.83) Estimate, Sales $84.51M Beat $65.78M Estimate

ABOS

ABSI

ACNT

ACTG

AENT

AGEN

AIOT

AIRG

ALIT

ALTG

AMBC

AMPS

AMTX

APEI

AREB

ARIS

ARMN

ATRA

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

AZTA

BHIL

BLDE

BLFS

BLTE

The Beachbody Company, Inc. Class A Common Stock

BODI

BRTX

BTMD

BTTR

BWAY

BXSL

BZFD

CAMT

CART

CATX

CAVA

CBAT

CBLL

CCLD

CGEN

CHGG

CHMI

CLSD

CNNE

CRNX

CRON

CRVS

CRWS

CVAC

CXAI

DAVA

DAVE

DRCT

DYAI

EARN

EGAN

ELMD

ETON

EVCM

EVGO

EYEN

FENG

FGEN

FIHL

FLNG

FOUR

FTCI

GENI

GENK

GMGI

GOVX

GRAL

GRDN

GROV

GRPN

GRVY

Earnings Scheduled For November 12, 2024

Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) is gearing up to announce its quarterly earnings on Tuesday, 2024-11-12. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Novavax will report an earnings per share (EPS) of $-0.87.
Anticipation surrounds Novavax's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Overview of Past Earnings</h3>
The company's EPS missed by $0.37 in the last quarter, leading to a 0.68% drop in the share price on the following day.
Here's a look at Novavax's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.36</td>
<td>-1.06</td>
<td>-0.45</td>
<td>-1.83</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.99</td>
<td>-1.05</td>
<td>-1.47</td>
<td>-1.26</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>99.0%</td>
<td>12.0%</td>
<td>-7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731358860_0.png" alt="eps graph" />
<h3>Tracking Novavax's Stock Performance</h3>
Shares of Novavax were trading at $8.91 as of November 08. Over the last 52-week period, shares are up 45.59%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/NVAX/earnings">To track all earnings releases for Novavax visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Novavax

Deep-pocketed investors have adopted a bullish approach towards Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in NVAX usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Novavax. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 77% leaning bullish and 22% bearish. Among these notable options, 7 are puts, totaling $300,278, and 2 are calls, amounting to $146,900.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $9.0 to $40.0 for Novavax during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Novavax stands at 5805.6, with a total volume reaching 12,344.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Novavax, situated within the strike price corridor from $9.0 to $40.0, throughout the last 30 days.
<h3>Novavax Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731354317_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVAX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$4.0</td>
<td>$3.65</td>
<td>$3.65</td>
<td>$10.00</td>
<td>$84.6K</td>
<td>17.4K</td>
<td>1.2K</td>
</tr>
<tr>
<td>NVAX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$0.77</td>
<td>$0.66</td>
<td>$0.78</td>
<td>$10.00</td>
<td>$77.9K</td>
<td>10.0K</td>
<td>1.0K</td>
</tr>
<tr>
<td>NVAX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$0.7</td>
<td>$0.69</td>
<td>$0.69</td>
<td>$9.50</td>
<td>$69.0K</td>
<td>1.0K</td>
<td>1.4K</td>
</tr>
<tr>
<td>NVAX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$4.0</td>
<td>$3.6</td>
<td>$3.6</td>
<td>$10.00</td>
<td>$57.6K</td>
<td>17.4K</td>
<td>1.9K</td>
</tr>
<tr>
<td>NVAX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$4.0</td>
<td>$3.65</td>
<td>$3.65</td>
<td>$10.00</td>
<td>$44.8K</td>
<td>17.4K</td>
<td>1.3K</td>
</tr>
</tbody>
</table>

<h3>About Novavax</h3>
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
In light of the recent options history for Novavax, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Novavax</h3>
<ul>
<li>Currently trading with a volume of 11,712,916, the NVAX's price is up by 1.42%, now at $9.04. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 1 days.</li>
</ul>
<h3>What Analysts Are Saying About Novavax</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $25.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Jefferies has decided to maintain their Buy rating on Novavax, which currently sits at a price target of $25. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Novavax, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Spotlight on Novavax: Analyzing the Surge in Options Activity

Novavax's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NYSE">NVAX</a>) short percent of float has risen 5.42% since its last report. The company recently reported that it has 35.72 million shares sold short, which is 27.83% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.51 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Novavax Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731340838_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Novavax has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Novavax's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Novavax's peer group average for short interest as a percentage of float is 13.10%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Novavax's Recent Short Interest

On Monday, the FDA removed the clinical hold on&nbsp;Novavax Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) Investigational New Drug (IND) application for its COVID-19-influenza combination (CIC) and stand-alone <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41877631/u-s-fda-removes-clinical-hold-on-novavaxs-covid-19-influenza-combination-and-stand-alone-influenza" rel="noreferrer noopener">influenza vaccine candidates</a>.
The FDA has cleared the company to begin enrolling the planned Phase 3 trial following the determination that Novavax satisfactorily addressed all clinical hold issues.
Novavax will be working with the clinical trial investigators and other partners to resume trial activities as quickly as possible.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40881276/desantis-administration-cautions-against-pfizer-moderna-mrna-covid-vaccines-for-vulnerable-indivi" rel="noreferrer noopener">DeSantis Administration Cautions Against Pfizer, Moderna mRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions</a>
In October, the FDA issued the clinical hold due to a spontaneous report of a serious adverse event (SAE) of motor neuropathy in a single CIC Phase 2 trial&nbsp;participant outside the U.S. who received the vaccine <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41356844/fda-puts-speed-breaker-on-novavaxs-covidflu-combo-shot-trial-on-concerns-related-to-damaged-nerve" rel="noreferrer noopener">in&nbsp;January 2023</a>.
The trial was completed in&nbsp;July 2023, and the participant reported the SAE in&nbsp;September 2024.
The FDA had requested additional information on this event. The additional information included a change in the event term to amyotrophic lateral sclerosis, a condition that is not known to be immune-mediated or associated with vaccination, which in this event was assessed as not related to vaccination.
Earlier this month, Novavax and the U.K. Health Security Agency, representing the U.K. Secretary of State for Health and Social Care, signed a Termination and Settlement Agreement and an amendment to resolve disputes over their updated COVID-19 vaccine supply contract <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41782824/why-is-covid-19-vaccine-maker-novavax-stock-trading-lower-on-wednesday" rel="noreferrer noopener">from July 1, 2022</a>.
Novavax is scheduled to release its third-quarter earnings tomorrow, Tuesday. Data from <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">Benzinga Pro</a> shows a consensus estimate of $(0.83) as adjusted EPS loss and revenues of $65.8 million.
Price Action: At last check on Monday, NVAX stock was up 14.30% to $10.18 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/41877573/cigna-not-pursuing-humana-merger-stock-soars" target="_blank" rel="noreferrer noopener">Cigna Not Pursuing Humana Merger, Stock Soars</a></li>
</ul>
Photo via Shutterstock

FDA Gives Green Signal To Novavax's COVID-19-Influenza Combo Vaccine Late-Stage Trial

Novavax shares are trading higher after the FDA removed the clical hold on the company's Investigational New Drug application for its COVID-19-Influenza Combination and stand-alone influenza vaccine candidates.

Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>), a global company advancing protein-based vaccines with its Matrix-M&trade; adjuvant, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on Novavax&#39;s Investigational New Drug (IND) application for its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine candidates. The FDA has cleared the Company to begin enrolling the planned Phase 3 trial following the determination that Novavax satisfactorily addressed all clinical hold issues. Novavax will be working with the clinical trial investigators and other partners to resume trial activities as quickly as possible.

U.S. FDA  Has Removed The Clinical Hold On Novavax's IND Application For Its COVID-19-influenza Combination And Stand-Alone Influenza Vaccine Candidates

On November 1, Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) and the U.K. Health Security Agency, representing the U.K. Secretary of State for Health and Social Care, signed a Termination and Settlement Agreement and an amendment to resolve disputes over their updated COVID-19 vaccine supply contract from July 1, 2022.
As per the SEC <a target="_blank" href="https://www.benzinga.com/secfilings/24/11/41760142/novavax-inc-general-corporate-statement-form8" rel="noreferrer noopener">filing</a>, the agreement releases both parties from any claims related to that prior contract.
As part of the settlement, Novavax and the U.K. Health Security Agency agreed to end the supply contract and settle disputed upfront payments Novavax previously received.
Under the terms, Novavax will refund $123.8 million to the U.K. agency in quarterly payments of $10.3 million over three years, with the final payment due by June 30, 2027.
This amount includes $11.3 million in interest, which can be avoided if Novavax pays ahead of schedule. According to the amendment, the first quarterly payment is due on November 30, 2024.
The two parties initially entered into a COVID-19 vaccine supply deal in 2020, and the United Kingdom government agreed to purchase 60 million doses of <a target="_blank" href="https://www.benzinga.com/general/biotech/20/08/17082187/novavax-to-supply-60m-coronavirus-vaccine-doses-to-uk-under-new-deal" rel="noreferrer noopener">its COVID-19 vaccine</a>.
The company's protein-based adjuvanted shot NVX-CoV2373 was renamed Nuvaxovid after being authorized by the U.K.'s Medicines and Healthcare Products Regulatory Agency <a target="_blank" href="https://www.benzinga.com/pressreleases/22/02/n25389592/medicines-and-healthcare-products-regulatory-agency-grants-conditional-marketing-authorization-for?_gl=1&#x2A;gc91sv&#x2A;_gcl_au&#x2A;MzExMDYwNy4xNzI5MTczNzIw&#x2A;_ga&#x2A;R1MxLjEuMTczMDkwODUxMy41MTUuMC4xNzMwOTA4NTIxLjAuMC4w&#x2A;_ga_V7ZK73W7N0&#x2A;MTczMDkwODUxMy41MTUuMS4xNzMwOTA5NjE3LjAuMC4w" rel="noreferrer noopener">(MHRA) in 2022</a>.
Recently, the FDA has placed a clinical hold on Novavax's Investigational New Drug (IND) application for its COVID-19-influenza combination (CIC) and stand-alone&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41356844/fda-puts-speed-breaker-on-novavaxs-covidflu-combo-shot-trial-on-concerns-related-to-damaged-nerve" rel="noreferrer noopener">influenza vaccine candidates</a>.
The clinical hold is due to a spontaneous report of a serious adverse event (SAE) of motor neuropathy in a single CIC Phase 2 trial&nbsp;participant outside the U.S. who received the vaccine in&nbsp;January 2023.
Earlier in October, the European Commission approved Novavax's updated 2024-2025 Nuvaxovid COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2705), dispersion for injection, for use in individuals aged 12 and older to prevent COVID-19&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41246672/novavaxs-updated-2024-2025-nuvaxovid-covid-19-vaccine-receives-authorization-in-the-eu" rel="noreferrer noopener">in the European Union</a>.
Price Action: NVAX stock is down 4.61% at $9.05 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41776963/colorectal-cancer-diagnostic-focused-exact-sciences-stock-plunges-on-weak-annual-gu" target="_blank" rel="noreferrer noopener">Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point</a></li>
</ul>
Photo via Shutterstock

Eurozone

Contracts

Why Is COVID-19 Vaccine Maker Novavax Stock Trading Lower On Wednesday?

Novavax's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NYSE">NVAX</a>) short percent of float has risen 5.42% since its last report. The company recently reported that it has 35.72 million shares sold short, which is 27.83% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.51 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Novavax Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730903424_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Novavax has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Novavax's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Novavax's peer group average for short interest as a percentage of float is 12.35%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Novavax?

On November 1, 2024, Novavax, Inc. (the "Company") and The Secretary of State for Health and Social Care, acting as part of the Crown, through the UK Health Security Agency (the "Authority"), entered into a Termination and Settlement Agreement (the "Settlement Agreement") and a Letter of Amendment to the Settlement Agreement (the "Settlement Agreement Amendment"), relating to the Amended and Restated SARS-COV-2 Vaccine Supply Agreement effective July 1, 2022 (the "Amended and Restated Supply Agreement") by and between the Company and the UK Secretary of State for Business, Energy and Industrial Strategy, acting on behalf of the Crown, settling the disputes regarding the Amended and Restated Supply Agreement and releasing both parties of all claims arising out of or connected with the Amended and Restated Supply Agreement.
&nbsp;
Under the terms of the Settlement Agreement, the Authority and the Company agreed to terminate the Amended and Restated Supply Agreement and to fully settle the outstanding amount under dispute related to upfront payments previously received by the Company from the Authority under the Amended and Restated Supply Agreement. Pursuant to the Settlement Agreement, the Company agreed to pay a refund of $123.8 million (the "Settlement Payment") to the Authority in equal quarterly installments of 10.3 million over a three year period, ending on June 30, 2027. The Settlement Payment amount includes a $11.3 million provision for interest over the period and may be avoided if the Company chooses to accelerate payments. Under the terms of the Settlement Agreement Amendment, the Authority and the Company agreed to make the first quarterly installment payment due on November 30, 2024.
&nbsp;

Global

Novavax And UK Health Security Agency End Disputes Over Vaccine Supply; Novavax To Refund $123.8M In Quarterly Installments Until 2027; First Payment Due November 30, 2024

Novavax, Inc. (NVAX) Q3 2024 Earnings Call Transcript

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Elliott has built a $5B+ stake in Hone...

Elliott confirms big Honeywell stake, Home Deport reports Q3 beat: Morning Buzz

In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target of $9.00....

Novavax: Navigating Fiscal Challenges and Strategic Shifts Amid COVID Vaccine Market Uncertainty

Novavax ( ($NVAX) ) has released its Q3 earnings. Here is a breakdown of the information Novavax presented to its investors. Novavax, Inc., based i...

Novavax Advances Vaccine Strategy Amid Financial Shifts

Shares of Novavax ($NVAX), a pharmaceutical company, declined over 6% following the release of its third-quarter results. Though the company report...

NVAX Earnings: Novavax Stock Down on Weak 2024 Revenue Outlook

Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price target to $12...

Novavax: Balancing Potential and Risk Amid Strategic Shifts and Uncertain Market Outlook

J.P. Morgan analyst Eric Joseph maintained a Sell rating on Novavax (NVAX – Research Report) yesterday and set a price target of $9.00. Eric Joseph...

Novavax's Market Share and Pipeline Uncertainties Lead to Sell Rating

Novavax Q3 Earnings Disappoint, But A Turnaround May Be Underway

President-elect Donald Trump said via Truth Social: "I am thrilled to announce Robert F. Kennedy Jr. as The United States Secretary of Health and H...

Trump names Robert Kennedy as Secretary of Health and Human Services

Vaccine makers close lower amid reports RFK Jr may head HHS

ABBV

ABNB

AMZN

ANGI

GOEV

HRTX

NVDA

ROST

SHOP

SNDX

ZETA

Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX

NVAX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Novavax, Inc. and Encourages Investors to Contact the Firm

Legal

Novavax to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Operational Highlights on November 12, 2024

U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial

Comments

Novavax

Noticias

Últimas noticias sobre Novavax (NASDAQ:NVAX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL